Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of California, Davis
Eli Lilly and Company
Tizona Therapeutics, Inc
Essen Biotech
BicycleTx Limited
Mayo Clinic
Merck Sharp & Dohme LLC
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seagen Inc.